Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim has selected a second Nanobody candidate for pre-clinical development, which resulted in a €5m milestone payment to Ablynx.
Subscribe to our email newsletter
The Nanobody development candidate is designed to interfere with the function of two distinct proteins that are thought to play a major role in human cancers.
To date, Ablynx has earned more than €57m in cash from the strategic alliance with Boehringer on the discovery, development and commercialisation of Nanobody therapeutics.
Ablynx CEO and chairman Edwin Moses said Boehringer has three Nanobody candidates in pre-clinical development including a Nanobody relevant in Alzheimer’s disease.
"We anticipate additional Nanobodies will be advanced into formal development during the next years," Moses added.